PR Newswire
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
📈
AI Sentiment
Highly Positive
10/10
- Home
- SERA
as of 01-08-2026 10:51am EST
$3.45
+$0.15
+4.55%
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 130.5M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 64.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $8.73 | Next Earning Date: | 11-13-2025 |
| Revenue: | $95,000 | Revenue Growth: | 1.06% |
| Revenue Growth (this year): | 25.84% | Revenue Growth (next year): | 347.37% |
AI-Powered SERA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 76.82%
76.82%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
Harrison Robert Gardner
Sell
Chief Information Officer
SERA Dec 30, 2025
Avg Cost/Share
$3.00
Shares
2,000
Total Value
$6,000.00
Owned After
84,788
SEC Form 4
Boniface John J.
Sell
Chief Scientific Officer
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
1,332
Total Value
$4,408.92
Owned After
150,397
SEC Form 4
Lindgardt Zhenya
Sell
Chief Executive Officer
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
4,155
Total Value
$13,753.05
Owned After
763,926
SEC Form 4
Kearney Paul
Sell
Chief Data Officer
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
1,213
Total Value
$4,015.03
Owned After
167,383
SEC Form 4
Jackson Benjamin
Sell
General Counsel
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
892
Total Value
$2,952.52
Owned After
118,866
SEC Form 4
Aerts Austin
Sell
Chief Financial Officer
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
873
Total Value
$2,889.63
Owned After
272,214
SEC Form 4
Harrison Robert Gardner
Sell
Chief Information Officer
SERA Dec 10, 2025
Avg Cost/Share
$3.31
Shares
616
Total Value
$2,038.96
Owned After
84,788
SEC Form 4
Lindgardt Zhenya
Sell
Chief Executive Officer
SERA Dec 9, 2025
Avg Cost/Share
$3.04
Shares
28,215
Total Value
$85,773.60
Owned After
763,926
SEC Form 4
Aerts Austin
Sell
Chief Financial Officer
SERA Dec 9, 2025
Avg Cost/Share
$3.04
Shares
5,232
Total Value
$15,905.28
Owned After
272,214
SEC Form 4
Kearney Paul
Sell
Chief Data Officer
SERA Dec 2, 2025
Avg Cost/Share
$2.94
Shares
32,203
Total Value
$94,676.82
Owned After
167,383
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Harrison Robert Gardner | SERA | Chief Information Officer | Dec 30, 2025 | Sell | $3.00 | 2,000 | $6,000.00 | 84,788 | |
| Boniface John J. | SERA | Chief Scientific Officer | Dec 10, 2025 | Sell | $3.31 | 1,332 | $4,408.92 | 150,397 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Dec 10, 2025 | Sell | $3.31 | 4,155 | $13,753.05 | 763,926 | |
| Kearney Paul | SERA | Chief Data Officer | Dec 10, 2025 | Sell | $3.31 | 1,213 | $4,015.03 | 167,383 | |
| Jackson Benjamin | SERA | General Counsel | Dec 10, 2025 | Sell | $3.31 | 892 | $2,952.52 | 118,866 | |
| Aerts Austin | SERA | Chief Financial Officer | Dec 10, 2025 | Sell | $3.31 | 873 | $2,889.63 | 272,214 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Dec 10, 2025 | Sell | $3.31 | 616 | $2,038.96 | 84,788 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Dec 9, 2025 | Sell | $3.04 | 28,215 | $85,773.60 | 763,926 | |
| Aerts Austin | SERA | Chief Financial Officer | Dec 9, 2025 | Sell | $3.04 | 5,232 | $15,905.28 | 272,214 | |
| Kearney Paul | SERA | Chief Data Officer | Dec 2, 2025 | Sell | $2.94 | 32,203 | $94,676.82 | 167,383 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
TMX Newsfile
Everkind, An AI-Powered Life Coach, Announces Closing of $3,000,000 Financing and the Formation of the Everkind Foundation
📈
AI Sentiment
Highly Positive
8/10
TMX Newsfile
Two Free Events with Astronaut Capt. Barry Wilmore and Ken Ham
âž–
AI Sentiment
Neutral
5/10
MT Newswires
Almonty Industries Appoints Guillaume Wisenbach de Lamaziere as Chief Development Officer
âž–
AI Sentiment
Neutral
5/10
MT Newswires
STAAR Surgical Shareholders Reject Proposed Alcon Merger; Shares Fall
📉
AI Sentiment
Negative
3/10
Mining Technology
MinRex to acquire Electrum shares in gold-copper merger
📈
AI Sentiment
Highly Positive
8/10
Retail Insight Network
Next lifts full-year profit outlook after strong Christmas trading
Compare SERA vs Leading Stocks
See how SERA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.